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aeruginosa, 21/30 B-Iact.amase producing Hemophilus infJuenzae, 6/15 B-lactamase producing
The quinolone carboxylic acid derivatives of nalidixic acid represent a new development in synthetic antimicrobial therapy and are a possible alterative to the more conventional B-lactam and aminoglycosides for the management of difficult nosocomial infections. This study compared the in '1itro antibacterial activity of ciprofloxadn, a new f1uroquinolone with lwelve. anlibiotics; six quinolones, three aminoglycosides and three cephalo porins. The in vivo safety and efficacy of cipronoxacin was determined in the treatment of patients with infections caused by multi-resistant gramnegative bacteria.
Abslract
The An open prospective study was undertaken to asse s the clinical and bacteriological efficacy of oral ciprofloxacin in the treatment of patients infected with multi-resistant gram negative bacteria. These included enterobacteriaceae resistant to ampicillin, sulphonamide and trimetboprim (on disc sensitivity testing by Stoke's method) and to gentamicin (MIC > 16 mg/L). All the isolates treated were fully sensitive to ciprofloxacin (MIC <.2 mg/L). Fifty-seven hospitalised patients (38 men and 19 women) were treated; the ages ranged from 18-93 years (mean age, 73).
The infections treated included bacteremia (12), urinary tract infection (37), bone (3), skin and soft tissue (5). Local ethical committee approval and informed consent from t.he patient or next of kin were obtained. Pregnant or lactating women, patients under 16 years of age and patients with hepatic or renal dysfunction were excluded from the study. A variable dosage regime was used according to the site and severity of infection. Ten patients were treated with 100 mg given 8 hourly, 13 with 250 mg 12 hourly, II with 250 mg 8 hourly and 23 with 500 mg 12 hourly. Clinically, radiological and bateriological parameters were used to evaluate response to therapy. Satisfactory clinical response was documented if improven~ent in signs and symptoms of infection occurred, Bacteriological cure was defined as elimination of the organism from culture sites on completion of therapy and also on follow up at seven days (and one month after therapy for urinary tract infections). Hematological and biochemical parameters were monitored throughout. The MIC of the antibiotics were determined by agar plate dilution method using Oxoid diagnostic sensitivity agar pH 7.3 supplemented with 7l1Jo lysed horse blood. Ten percent horse serum was added to support the growth of Streptococcus pneumoniae. A final inoculum of lO'cfu/ml was delivered via a multipont inoculator (Denley Tech Ltd.). The organisms were incubated fOT 24 hours aerobically at 37°C except for H. inJluenzae, Branhamella calarrhalis and campylobacter which were incubated in 10% C02' The Oxford strain of Staph. aureus and E. coli NCTC 10418 were used as controls. The MIC of the antibiotic against all organisms were defined as the lowest concentration of drug which inhibited visble growth.
Morgonella morganii (I), and Ps. aeruginosa (I).
Thirty-three patients were treated successfully and 38 of the 42 isolates were eradicated.
Associated soft tissue infections in six patients were treated successfully. Three patients were treated for bone infection, which included a Brodie's abscess infected with Salmonella munchen, and two total hip replacement infected with E. coli. The latter two persisted after 60 and 120 days therapy with ciprofloxacin. Five patients including a petient with salpingitis caused by B-lactamase producing N. gonorrhoeae and two patients with arterial infection caused by Ps. oeruginosa were treated (the latter again showed persistence after 60 days of therapy, although clinical improvement had occurred).
Twelve cases of basteremia were treated successfully and included E. coli (4) Ps. aeruginosa (2) . A patient with Salmonella typhimurium (resistant to ampicillin, contrimoxazone and chloramphenicol) septicemia was treated with 4 days of intravenous ciprot1oxacin and then changed to oral ciprofloxacin, recovered completely after 14 days therapy. Sixty-eight bacterial strains were isolated from 57 patients; all but eight were eliminated with ciprofloxacin therapy. Bacterial persistence in three patients was associated with urinary tract infection, in catheterised patients. They were caused by Ps. aeruginosa and two by E. coli, in patients with prostheses. Four organisms; Klebsiella (2) and Pseudomonas (2) demonstrated an increase in ciprot1oxacin MIC during therapy. The former was resistant to ampicillin, sulphonamide, trimethoprim and nalidixic acid.
Two patients uffered nausea and vomiting as side effects, and another had transient rise in liver function tests during therapy, which returned to normal at the end of therapy. The overaJi results showed 9)<1' 10 clinical success rale and 860/0 bacterial eradication rate.
Erratum:
10 the article by Malik-Afzali and Chamsa, entitled "Neonatal MOlality Due to Tetanus in Iran" (JiMA 1988;20: 104-110), the following corrections should be noted: Page 104, Abstract, line 6: over 1,000 childrenshould read: over 10,000 children. Page lOS, Table 1 , column "Live Binh":tolal
Discussion
This study showed that in vitro ciprofloxacin was the most active quinolone against aerobic gram negative coliforms. It has moderate activity against Pseudomonas species and the gram positive organisms and is inactive against the anaerobic organisms. I There is no cross resistance with the B-Iactam antibiotics or with the aminoglycosides. Nalidixic acid resistance raises the MlC by 4-fold for all the quinolones.
1
In vivo it is well tolcrated and effective in treating multi-resistant gram negative infections including bacteraemias. J,' Persistence of the organism after therapy was noted when the infection was associated with a foreign body e.g. catheter or prosthesis, or initial nalidixic acid resistance. Pseudomonas aeruginosa, a difficult organism to treat, requiring a combination of B-lactam and aminoglycoside therapy can be treated effectively with high dose oral ciprolloxacin.
Ciprofloxacin as a representative of the quinlone group, heralds a new era in antibiotic therapy for multi-resistant gram negative coliforms.
